The global plasma fractionation market size was valued at USD 39.89 billion in 2025 and is projected to grow from USD 43.16 billion in 2026 to USD 81.08 billion by 2034, registering a CAGR of 8.2% during the forecast period from 2026 to 2034. North America dominated the plasma fractionation market with a market share of 39.5% in 2025.
Plasma fractionation is a large-scale process used to separate human blood plasma into individual protein fractions that can be purified and used to produce medicines. Plasma contains many proteins with different biological functions, so fractionation uses physical and chemical techniques such as precipitation and chromatography to isolate specific proteins. Additional purification and safety steps may be used to remove unwanted substances and reduce the risk of blood-borne infections. The resulting plasma-derived products include immunoglobulins, coagulation factors, albumin, fibrinogen, and other therapeutic proteins used in the treatment of various medical conditions. The World Health Organization and U.S. FDA recognize plasma fractionation as an important process for producing plasma-derived medicinal products.
Download a Free Sample To learn more about this report,
Growing Demand for Plasma-Derived Therapies Drives Fractionation Capacity Expansion
The plasma fractionation market is expanding as healthcare systems face sustained demand for plasma-derived medicines used to treat immunodeficiencies, bleeding disorders, and other rare and chronic conditions. Immunoglobulins remain an important area of demand, encouraging manufacturers to improve plasma processing efficiency and expand fractionation infrastructure. Companies are also investing in new production facilities and technologies to make better use of donated plasma and strengthen the long-term supply of essential therapies. CSL has highlighted opportunities to improve immunoglobulin and albumin yields through better plasma allocation, data analytics, and operational improvements.
For instance, in July 2025, Grifols announced plans for a new plasma fractionation facility in Lliçà de Vall, Spain, aimed at strengthening its European manufacturing network and responding to growing demand for plasma-derived medicines. The facility is being developed as part of a highly digitalised biotechnology hub and is designed to support more efficient and sustainable plasma processing.
Regional Plasma Self-Sufficiency Strengthens Global Supply Chains
The plasma fractionation market is increasingly moving toward regional supply models as governments and manufacturers seek greater control over the availability of plasma-derived medicines. Countries are developing local plasma collection networks, fractionation facilities, testing infrastructure, and integrated supply chains to reduce dependence on imported plasma products. This trend is particularly visible in emerging markets, where building domestic plasma capabilities can improve the reliability of treatment supplies and strengthen healthcare resilience.
For instance, in June 2026, Grifols expanded its plasma-derived medicines program in Egypt through a new growth plan focused on expanding plasma collection and industrial capacity. The initiative is developing an integrated plasma ecosystem that brings together donation centres, plasma testing, logistics, and fractionation capabilities, supporting Egypt's goal of greater self-sufficiency in plasma-derived medicines.
Rising Demand for Plasma-Derived Medicines
The plasma fractionation market is being driven by increasing demand for plasma-derived medicinal products, particularly immunoglobulins, albumin, and coagulation factors. These therapies are used to manage immunodeficiency disorders, bleeding conditions, and other serious diseases, making a reliable supply of fractionated plasma increasingly important. The World Health Organization emphasizes that governments need sustainable plasma and blood programs to ensure adequate supplies of immunoglobulins and coagulation factors. This is strengthening plasma fractionation market demand and influencing plasma fractionation market trends toward greater collection and processing capacity.
For instance, in February 2025, Octapharma completed a major expansion of its Vienna manufacturing site with a €200 million investment, increasing production volumes by 50% to meet rising demand for plasma-based medicines. The facility produces plasma-derived products for haemophilia, immunology, and intensive care applications, strengthening the company's fractionation and manufacturing capacity.
Limited Availability of Plasma Donations and Supply Chain Dependence
The market faces restraints because plasma collection depends on a sufficient and consistent donor base. Collection capacity can vary considerably between countries, while some regions remain highly dependent on imported plasma-derived medicines. The WHO reports that only a limited number of countries fractionate domestically collected plasma, with many countries relying on imports for plasma-derived medicinal products. These limitations create plasma fractionation industry challenges and can restrict the ability of manufacturers to respond quickly to increasing therapeutic requirements.
For instance, in July 2025, the European Medicines Agency and Heads of Medicines Agencies issued recommendations addressing vulnerabilities in the supply chain of anti-D immunoglobulins. The agencies identified declining donor numbers, limited manufacturing capacity, a small number of plasma collection centres, and dependence on non-EU countries as important vulnerabilities, highlighting the difficulty of maintaining a stable plasma supply.
Expansion of Domestic Plasma Collection and Fractionation Capacity
The market presents significant opportunities through the expansion of domestic plasma collection programs and local fractionation infrastructure. Governments are increasingly looking to strengthen self-sufficiency in plasma-derived medicines and reduce dependence on international supply chains. Investment in donor centres, fractionation facilities, purification technologies, and integrated manufacturing networks can create new plasma fractionation market opportunities while supporting long-term plasma fractionation market growth. The WHO has also highlighted policy approaches that allow countries to use domestic plasma through contract or toll fractionation arrangements.
For instance, in July 2025, Grifols announced a €160 million investment to build a new plasma fractionation facility in Lliçà de Vall, Spain. The site is expected to double the company's plasma fractionation capacity in Europe and is planned to produce plasma-derived medicines for more than 300,000 patients across the continent. The facility is also designed to operate using renewable electricity and digital resource-management systems.
Maintaining Supply Resilience While Expanding Plasma Processing
The plasma fractionation market continues to face the challenge of maintaining a reliable supply of plasma while expanding processing capacity and meeting stringent quality and safety requirements. Fractionation involves multiple stages of plasma collection, testing, pooling, separation, purification, and manufacturing, making the supply chain highly dependent on consistent donor availability and efficient processing. Shortages of immunoglobulins in several European markets have demonstrated how disruptions or unexpected increases in demand can place pressure on the supply of plasma-derived medicines. These conditions are shaping the plasma fractionation market outlook and encouraging investment in more resilient collection and manufacturing systems.
For instance, in March 2025, Octapharma announced that NHS patients had begun receiving immunoglobulin and albumin medicines manufactured using UK-donated plasma for the first time in almost 30 years. The development formed part of the UK's Plasma for Medicines programme, which aims to strengthen domestic supply resilience and reduce reliance on external plasma sources.
Immunoglobulins Segment Dominated the Plasma Fractionation Market with 39.8% Share in 2025
The immunoglobulins segment dominated the global plasma fractionation market with a 39.8% share in 2025, driven by the widespread use of immunoglobulin therapies for the treatment of immune deficiencies, autoimmune disorders, and neurological conditions. Growing awareness of plasma-derived therapies, increasing diagnosis of immune-related diseases, and continued demand for intravenous and subcutaneous immunoglobulin products are supporting the strong position of this segment. Expanding plasma collection and fractionation capacity is also helping manufacturers respond to rising demand for immunoglobulin-based therapies.
The albumin segment remains an important part of the market due to its extensive use in fluid replacement, critical care, surgery, liver disease management, and other medical applications. Coagulation factors continue to support treatment for bleeding disorders, particularly hemophilia, while protease inhibitors are used in the management of specific inherited and acquired conditions. Other plasma-derived products continue to serve specialised therapeutic needs across healthcare settings.
Request Customizationto receive a tailored report.
Chromatography Segment is Projected to Register the Fastest Growth in the Plasma Fractionation Market at a CAGR of 8.15%
The chromatography segment is projected to register the fastest growth in the global plasma fractionation market at a CAGR of 8.15% during 2026–2034, driven by its ability to provide highly selective separation and purification of plasma proteins. Chromatography enables manufacturers to achieve high product purity and improved process control, making it increasingly important for the production of complex plasma-derived therapeutics. Continued technological improvements and the growing demand for high-quality fractionated plasma products are supporting its adoption.
Centrifugation remains widely used as an established separation method because of its effectiveness in processing large volumes of plasma and its integration into conventional fractionation workflows. Depth filtration continues to support efficient removal of impurities and clarification during plasma processing, while other methods contribute to specialised purification and separation requirements across different production processes.
Neurology Segment Dominated the Plasma Fractionation Market with 31.6% Share in 2025
The neurology segment dominated the global plasma fractionation market with a 31.6% share in 2025, supported by the growing use of plasma-derived therapies in the management of neurological and immune-mediated disorders. Immunoglobulin therapies are increasingly used for conditions requiring immune modulation, while greater disease awareness, improved diagnosis, and expanding access to specialised treatments are supporting demand in neurological applications. Continued research into plasma-derived therapies for neurological conditions is also contributing to the segment's importance.
The hematology segment remains a major application area due to the use of plasma-derived products in the management of bleeding and blood-related disorders. Oncology applications continue to expand as plasma-derived therapies support selected treatment and supportive-care needs. Immunology remains an important area because of the growing use of immunoglobulin therapies for immune deficiencies and autoimmune conditions. Pulmonology and other applications continue to contribute through specialised uses of plasma-derived products across different therapeutic areas.
Clinical Research Segment is Projected to Register the Fastest Growth in the Plasma Fractionation Market at a CAGR of 8.05%
The clinical research segment is projected to register the fastest growth in the global plasma fractionation market at a CAGR of 8.05% during 2026–2034, driven by increasing research into plasma-derived therapies, protein purification, and novel therapeutic applications. Growing clinical investigation of immunoglobulins and other plasma-derived products is creating additional demand for high-quality fractionated plasma materials. Advances in biotechnology and pharmaceutical research are further supporting the use of plasma fractionation products in clinical development and research activities.
Hospitals and clinics remain the primary end users of plasma fractionation products because of the widespread use of albumin, immunoglobulins, coagulation factors, and other plasma-derived therapies in routine and specialised patient care. Other end users, including specialised healthcare and research settings, continue to support demand for fractionated plasma products across a range of therapeutic and scientific applications.
Speak to an Analystto discuss market opportunities.
North America accounted for the largest share of the global plasma fractionation market, representing 39.5% of total revenue and reaching USD 15.76 billion in 2025. The region is projected to grow at a CAGR of 6.85% during 2026–2034. Strong demand for plasma-derived therapies, established healthcare infrastructure, growing use of immunoglobulins and albumin, and continued investment in plasma collection and fractionation capacity are supporting regional market growth. Increasing awareness of plasma-based treatments and the need for therapies for immune and bleeding disorders are also contributing to demand.
The US market was valued at approximately USD 13.20 billion in 2025, making it the largest contributor in North America. A well-developed plasma collection network, high demand for immunoglobulin therapies, and extensive use of plasma-derived products in hospitals and specialty care continue to support market growth. Ongoing investment in plasma collection capacity and manufacturing technologies is also strengthening the country's position.
Canada's market reached approximately USD 2.56 billion in 2025. Demand is supported by the use of plasma-derived medicines for immune deficiencies, bleeding disorders, and other chronic conditions. Continued development of plasma collection capabilities and growing healthcare requirements are contributing to steady market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific accounted for 22.4% of the global plasma fractionation market, valued at USD 8.94 billion in 2025, and is projected to register the fastest CAGR of 8.65% during 2026–2034. Rising healthcare expenditure, expanding access to plasma-derived therapies, increasing diagnosis of immune and bleeding disorders, and improvements in healthcare infrastructure are driving regional growth. Growing investment in domestic plasma collection and fractionation capacity is also helping countries strengthen the availability of essential plasma products.
Japan's market generated approximately USD 1.60 billion in 2025. Strong healthcare infrastructure, an aging population, and established demand for plasma-derived medicines continue to support market development. Increasing use of immunoglobulins and other plasma-derived therapies in clinical care is contributing to sustained demand.
China accounted for a major share of the Asia Pacific market, reaching approximately USD 4.50 billion in 2025. Expanding healthcare access, rising demand for immunoglobulins and albumin, increasing investment in plasma collection, and development of domestic biopharmaceutical manufacturing are supporting market growth. Greater availability of plasma-derived therapies is expected to create additional opportunities during the forecast period.
Europe accounted for 27.8% of the global plasma fractionation market, reaching USD 11.09 billion in 2025, and is projected to grow at a CAGR of 6.95% during 2026–2034. The regional market benefits from established healthcare systems, widespread use of plasma-derived medicinal products, strong pharmaceutical capabilities, and increasing demand for immunoglobulins and albumin. Continued efforts to strengthen plasma supply and improve access to essential plasma-derived therapies are supporting market development.
The UK market was valued at approximately USD 1.50 billion in 2025. Demand for plasma-derived therapies is supported by established healthcare services and the treatment of immune deficiencies, bleeding disorders, and other conditions requiring plasma products. Continued focus on plasma collection and supply security is contributing to market development.
Germany's market accounted for approximately USD 2.40 billion in 2025. A well-developed healthcare system, strong pharmaceutical industry, and established use of immunoglobulins, albumin, and other plasma-derived medicines continue to support demand. Increasing healthcare requirements and investment in advanced biopharmaceutical production are also contributing to market growth.
Middle East and Africa accounted for 4.2% of the global plasma fractionation market, totalling USD 1.68 billion in 2025, and is projected to grow at a CAGR of 6.55% during 2026–2034. Expanding healthcare infrastructure, increasing access to plasma-derived medicines, improving diagnosis of immune and bleeding disorders, and rising healthcare investment are supporting regional growth. Greater awareness of plasma-based therapies is also creating opportunities for market expansion.
The UAE market was valued at approximately USD 0.30 billion in 2025. Increasing healthcare investment, development of advanced medical infrastructure, and growing access to specialty medicines are supporting demand for plasma-derived therapies. The country's focus on expanding healthcare capabilities is expected to create further opportunities.
Africa's market reached approximately USD 1.38 billion in 2025. Expanding healthcare infrastructure, improving access to specialized treatments, and increasing awareness of plasma-derived medicines are supporting gradual market development. Greater investment in healthcare systems, pharmaceutical supply chains, and treatment capabilities is expected to improve access to plasma-based therapies across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Flow Cytometry Market Size, Share, Growth, Analysis, Report, 2034
Gene Synthesis Market Size, Share, Growth, Analysis, Report, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Single-Use Assemblies Market Size, Share, Growth, Analysis, 2034
Cancer Microbiome Sequencing Market Size, Share, Growth, 2034
Inhaled Biologics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com